Daniel Gallo

Daniel Gallo, PhD, has extensive work experience in the medical field, particularly in medical affairs and advocacy. Daniel is currently the Senior Vice President of Medical Affairs and Advocacy at Zevra Therapeutics since January 2023. Prior to this, they served as the Vice President and Head of Medical Affairs at Jaguar Gene Therapy from January 2022 to January 2023. From July 2020 to January 2022, they held the position of Vice President and Head of US Medical Affairs at Orphazyme A/S. Before that, they worked as the US Medical Director of Compliment Inhibitors at Sanofi Genzyme from January 2020 to July 2020. Daniel also has experience as an MSL Director in neuroscience and psychiatry at Syneos Health from July 2018 to February 2020. Additionally, they have worked in various roles at AbbVie, Shire, GSK, and Teva Pharmaceuticals, where they gained expertise in areas such as antivirals, hepatology, hematology, and respiratory medicine. Daniel also worked as an Adjunct Faculty at Loyola University Chicago in clinical infectious diseases, immunology, and biology.

Daniel Gallo holds a Doctor of Philosophy (PhD) degree in Cell and Molecular Biology and Biochemistry from Northwestern University. Daniel also obtained a Bachelor's of Science degree in Cellular and Molecular Biology from the University of Illinois Urbana-Champaign.